Low Plasma Fibrinogen Levels with the Clauss Method during Anticoagulation with Bivalirudin
Molinaro, Ross J. Ph.D., M.T.(A.S.C.P.); Szlam, Fania M.M.Sc.; Levy, Jerrold H. M.D.; Fantz, Corinne R. Ph.D.; Tanaka, Kenichi A. M.D., M.Sc.*
To the Editor:—
Bivalirudin is a bivalent direct thrombin inhibitor (DTI) with a plasma half-life of approximately 25 min. It is increasingly used as a heparin alternative in percutaneous coronary intervention procedures,1
and in cardiac surgical patients with heparin-induced thrombocytopenia.2,3
The anticoagulant effect of bivalirudin usually is monitored with activated clotting time, but the utility of viscoelastic monitors, including Thrombelastograph® or thromboelastometry (e.g.
, ROTEM®; Pentapharm, Munich, Germany), has been recently demonstrated by us and the other group.4,5
We herein describe a case in which bivalirudin monitoring with ROTEM® was found useful. A 68-yr-old, 110-kg female was diagnosed with acute myocardial infarction. The cardiac catheterization showed ostial occlusion of left anterior descending artery, 90% stenosis of right coronary artery, and 40% stenosis of circumflex artery. Past medical history was notable for hypertension, hypercholesterolemia, type II diabetes, chronic anemia, and mild cirrhosis. Given her previous history of heparin-induced thrombocytopenia and persistent antibody titer on admission, she was treated with argatroban infusion at 0.5 μg · kg · min until 4 h before the scheduled off-pump coronary bypass graft surgery. Baseline laboratory results showed hematocrit 33.3%, platelet 111 × 103
, fibrinogen 432 mg/dl, partial thromboplastin time 73.8 s, and celite-activated clotting time 188 s. For anticoagulation, bivalirudin was given at 0.75 mg/kg, followed by infusion at 0.75 mg · kg · h, according to her ideal body weight (70 kg). This regimen maintained activated clotting time above 400 s, and delayed tissue factor induced thrombus formation on ROTEM® (fig. 1A
). Bivalirudin infusion was stopped at the beginning of proximal anastomoses, and laboratory values were hematocrit 21%, platelet 103 × 103
, and activated clotting time 278 s at the end of three-vessel bypass procedure. Two units of packed red blood cells were administered, and infusion of tranexamic acid 2 mg · kg · h was started. Notably, the plasma fibrinogen level using the modified Clauss method (BCS®, Dade Behring, Deerfield, IL) was reported at that time as less than 60 mg/dl, but the ROTEM®-based fibrinogen assay (maximal clot formation of FibTEM® [Pentapharm, Munich, Germany]) indicated functional fibrinogen level6
throughout the bivalirudin infusion (fig. 1A
). The postoperative chest tube drainage was 180 ml over 12 h.
To evaluate the effect of direct thrombin inhibitors (DTIs) on the fibrinogen measurements using the modified Clauss method, argatroban, bivalirudin, lepirudin, and heparin at various concentrations were added in vitro
to the pooled human plasma, (CRYOcheck lot No. A1044; PrecisionBioLogic, Dartmouth, Nova Scotia). The concentrations of DTIs and heparin used in our study span from therapeutic to supratherapeutic levels according to the reported plasma (molar) concentrations; argatroban 1–5 μg/ml (2–10 μm), bivalirudin 2–20 μg/ml (1–10 μm), lepirudin 1–5 μg/ml (0.15–0.75 μm), and heparin 0.4–4 U/ml.7–9
The measured fibrinogen level in the presence of three DTIs and heparin was progressively lowered in the BCS® system relative to the baseline measurement (311 ± 7.6 mg/dl), and it also was affected to a lesser extent in the STA-R Evolution® system (Diagnostica-Stago, Parsippany, NJ) (table 1
). The fibrinogen measurements using the maximal clot formation parameter of ROTEM® were unchanged when the spiked plasma samples were recalcified and activated with tissue factor, although DTIs delayed the clotting process (fig. 1B
). Because bovine thrombin is used as a reagent for these assays based on the modified Clauss method,10
test results are susceptible to antithrombin effects of DTIs and heparin. This effect was more evident at therapeutic concentrations of bivalirudin tested when using the BCS® system compared with STA-R® (table 1
). The difference may be attributed to the clot detection mechanisms, or different amounts of exogenous thrombin added for clotting. The BCS® system derives fibrinogen levels using photo-optical turbidity changes, whereas STA-R® magnetically senses an increased viscosity due to clotting using the pendulum motion of a steel ball. The rate of change in turbidity (i.e.
, fibrin polymerization) is clearly affected by DTIs, particularly argatroban (table 1
). The STA-R® and ROTEM® maximal clot formation seem to be less susceptible to DTIs, due to their viscosity detection mechanisms, but α-angle of ROTEM®, which reflects the rate of fibrin polymerization, is reduced by DTIs (fig. 1B
Our present data demonstrate that fibrinogen measurements are affected in the order of argatroban > bivalirudin > lepirudin for the BCS® method. Because the molecular weight of argatroban (527 Da) is much smaller than that of bivalirudin and lepirudin (2,180 Da and 6,980 Da, respectively), exogenously added thrombin for the fibrinogen assay is more inhibited in the molar excess of argatroban. Similarly, Warkentin et al.12
previously demonstrated that DTIs affect prothrombin time in a molar concentration dependent manner, thus therapeutic concentrations of argatroban prolong prothrombin time more than bivalirudin and lepirudin. Heparin also affects fibrinogen measurements, but less extensively than lepirudin (table 1
). Presently, there is no antidote for anticoagulation with DTIs. Low fibrinogen levels during DTI therapy may worsen bleeding because all DTIs compete with fibrinogen for thrombin. The maintenance of fibrinogen levels is critical in achieving hemostasis after cardiac surgery.13,14
In summary, we demonstrate the turbidmetric fibrinogen assay is particularly affected by DTIs, and falsely low fibrinogen levels are reported during bivalirudin anticoagulation. The modified thromboelastometry using abciximab or cytochalasin D can be used to assess functional fibrin polymerization, and it may be useful for evaluating hemostatic function and recovery from bivalirudin therapy.5,6,15
Ross J. Molinaro, Ph.D., M.T.(A.S.C.P.)
Fania Szlam, M.M.Sc.
Jerrold H. Levy, M.D.
Corinne R. Fantz, Ph.D.
Kenichi A. Tanaka, M.D., M.Sc.*
*Emory University School of Medicine, Atlanta, Georgia. email@example.com
1. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade versus heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292:696–703
2. Merry AF, Raudkivi PJ, Middleton NG, McDougall JM, Nand P, Mills BP, Webber BJ, Frampton CM, White HD: Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:925–31
3. Dyke CM, Koster A, Veale JJ, Maier GW, McNiff T, Levy JH: Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg 2005; 80:299–303
4. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK: Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 2006; 25:653–63
5. Tanaka KA, Szlam F, Sun HY, Taketomi T, Levy JH: Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg 2007; 105:933–9
6. Lang T, Toller W, Gutl M, Mahla E, Metzler H, Rehak P, Marz W, Halwachs-Baumann G: Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004; 2:147–53
7. Jang I-K, Lewis BE, Matthai WH Jr, Kleiman NS: Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004; 18:31–7
8. Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD: Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 2003; 96:383–6
9. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JI, Goodnough LT: More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76:902–8
10. Tan V, Doyle CJ, Budzynski AZ: Comparison of the kinetic fibrinogen assay with the von Clauss method and the clot recovery method in plasma of patients with conditions affecting fibrinogen coagulability. Am J Clin Pathol 1995; 104:455–62
11. Chakroun T, Gerotziafas GT, Seghatchian J, Samama MM, Hatmi M, Elalamy I: The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile. Thromb Haemost 2006; 95:822–8
12. Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard J-AI, Ofosu FA: Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94:958–64
13. Blome M, Isgro F, Kiessling AH, Skuras J, Haubelt H, Hellstern P, Saggau W: Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93:1101–7
14. Tanaka KA, Taketomi T, Szlam F, Calatzis A, Levy JH: Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg 2008; 106:732–8
15. Gottumukkala VNR, Sharma SK, Philip J: Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women. Anesth Analg 1999; 89:1453–5
This article has been cited 7 time(s).
Intensive Care MedicineDirect thrombin inhibitors: pharmacology and application in intensive care medicineIntensive Care Medicine
Anesthesia and AnalgesiaBlood Coagulation: Hemostasis and Thrombin RegulationAnesthesia and Analgesia
Neurocritical CareBivalirudin as a Bridge for Anticoagulation in High Risk Neurosurgical Patients with Active DVT or High Risk of ThrombosisNeurocritical Care
Liver InternationalClinical utility of viscoelastic tests of coagulation in patients with liver diseaseLiver International
Anasthesiologie & Intensivmedizin
Dealing with Massive Bleeding and associated perioperative Coagulation Defects (DGAI Recommended Action), Response
Anasthesiologie & Intensivmedizin, 54():
Journal of Cardiothoracic and Vascular AnesthesiaDiagnosis of Perioperative Coagulopathy-Plasma versus Whole Blood TestingJournal of Cardiothoracic and Vascular Anesthesia
Acta Anaesthesiologica ScandinavicaEarly thromboelastometric variables reliably predict maximum clot firmness in patients undergoing cardiac surgery: a step towards earlier decision makingActa Anaesthesiologica Scandinavica
© 2008 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.